Recombinant vaccines for COVID-19

Abstract

SARS-CoV-2, the causative agent of COVID-19, has imposed a major public health threat, which needs effective therapeutics and vaccination strategies. Several potential candidate vaccines being rapidly developed are in clinical evaluation. Considering the crucial role of SARS-CoV-2 spike (S) glycoprotein in virus attachment, entry, and induction of neutralizing antibodies, S protein is being widely used as a target for vaccine development. Based on advances in techniques for vaccine design, inactivated, live-vectored, nucleic acid, and recombinant COVID-19 vaccines are being developed and tested for their efficacy. Phase3 clinical trials are underway or will soon begin for several of these vaccines. Assuming that clinical efficacy is shown for one or more vaccines, safety is a major aspect to be considered before deploying such vaccines to the public. The current review focuses on the recent advances in recombinant COVID-19 vaccine research and development and associated issues.

Type 1 Kounis Syndrome Induced by Inactivated SARS-COV-2 Vaccine

“…Nowadays, different COVID-19 vaccines are being to used for immunity around the world. Some of these are inactive-attenuated virus vaccines, protein subunit-based vaccines, non-replicating viral vector vaccines, and DNA-based or RNA-based vaccines [1].…”

Different Therapeutic Strategies to Tackle the Infection Associated with COVID-19

“…Now in covid-19 emergency, vaccines could only be considered as potent therapeutics against SARS-CoV-2 deadly virus which normalize social life and working environment as it was earlier before pandemic. For the effective vaccines development against SARS-CoV-2 virus, various components are being used which include inactive or live-attenuated viruses, virus-like particles, viral vectors, protein-based, DNA-based, and mRNAbased vaccines [89]. Till now various potential vaccine candidates have already been *Address all correspondence to: tusingh80@gmail.com developed and undergone for vaccination shot which have completed their clinical evaluation phase successfully [90].…”

Therapeutic approaches for SARS-CoV-2 infection

“…However, RBD surface often have distinct antibodies escape mutations [193] overtime. Hence, a detailed review covering all the aspects of vaccine design and development using recombinant technology has recently been published by our group [194] .…”